GlassScriptPhysician profile
Ann I Payne-Johnson
NPI 1174652275
$1,182.12
in general payments reported to CMS, 2019-2025
23 companies · $192 in 2025
The $192 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $689 · 2022: $50.36 · 2023: $79.29 · 2024: $171 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $442.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $398.46 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $90.42 | 2019-2025 | Zepbound, Mounjaro |
| Horizon Therapeutics Plc | $84.68 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $83.54 | 2019-2025 | Breztri |
| Vivus LLC | $77.75 | 2019 | |
| Corcept Therapeutics | $65.88 | 2024 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.95 | 2019-2025 | Xifaxan |
| Amgen INC. | $38.50 | 2019-2025 | Repatha |
| Dexcom, INC. | $35.75 | 2024-2025 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $28.00 | 2022-2023 | Quviviq |
| Eisai INC. | $26.89 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.34 | 2019 | |
| Exact Sciences Corporation | $22.04 | 2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $21.24 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.92 | 2025 | Caplyta |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $18.42 | 2019 | |
| Pfizer INC. | $17.83 | 2022 | |
| Glaxosmithkline, LLC. | $17.64 | 2023 | Shingrix |
| Genentech USA, INC. | $16.47 | 2019 | |
| Hologic Sales and Service, LLC | $13.66 | 2025 | Affirm Prone Biopsy System |
| Merck Sharp & Dohme LLC | $13.36 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $11.33 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Payne-Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.